Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 99

1.

Validation of the triple timed up-and-go test in Lambert-Eaton myasthenia.

Raja SM, Sanders DB, Juel VC, Harati Y, Smith AG, Pascuzzi R, Richman DP, Wu A, AleŇ° KL, Jacobus LR, Jacobus DP, Guptill JT; DAPPER Study Team.

Muscle Nerve. 2019 Sep;60(3):292-298. doi: 10.1002/mus.26625. Epub 2019 Jul 18.

PMID:
31269226
2.

Immune Checkpoint Inhibitor-Induced Myasthenia Gravis in a Patient with Advanced NSCLC and Remote History of Thymoma.

Lara MS, Afify A, Ellis MP, Phan CT, Richman DP, Riess JW.

Clin Lung Cancer. 2019 Jul;20(4):e489-e491. doi: 10.1016/j.cllc.2019.04.007. Epub 2019 Apr 19. No abstract available.

PMID:
31085042
3.

Reply.

Sanders DB, Harati Y, Juel VC, Lou JS, Marburger T, Pascuzzi RM, Peltier AC, Richman DP, Smith AG.

Muscle Nerve. 2018 May;57(5):E130-E131. doi: 10.1002/mus.26089. Epub 2018 Mar 1. No abstract available.

PMID:
29406616
4.

3,4-diaminopyridine base effectively treats the weakness of Lambert-Eaton myasthenia.

Sanders DB, Juel VC, Harati Y, Smith AG, Peltier AC, Marburger T, Lou JS, Pascuzzi RM, Richman DP, Xie T, Demmel V, Jacobus LR, AleŇ° KL, Jacobus DP; Dapper Study Team.

Muscle Nerve. 2018 Apr;57(4):561-568. doi: 10.1002/mus.26052. Epub 2018 Feb 2.

5.

Acute Stroke Despite Dabigatran Anticoagulation Treated with Idarucizumab and Intravenous Tissue Plasminogen Activator.

Bissig D, Manjunath R, Traylor BR, Richman DP, Ng KL.

J Stroke Cerebrovasc Dis. 2017 Jun;26(6):e102-e104. doi: 10.1016/j.jstrokecerebrovasdis.2016.12.037. Epub 2017 Apr 14.

PMID:
28416406
6.

Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study.

Dimachkie MM, Abuzinadah AR, Barohn RJ, Oskarsson B, Rocke DM, Dengel K, Richman DP.

Neurology. 2016 Nov 8;87(19):2067-2068. No abstract available.

PMID:
27821567
7.

Lipoprotein-like receptor 4 antibodies in myasthenia gravis: pathogenic or protective.

Richman DP.

Eur J Neurol. 2016 Nov;23(11):1593-1594. doi: 10.1111/ene.13169. No abstract available.

PMID:
27753233
8.

International consensus guidance for management of myasthenia gravis: Executive summary.

Sanders DB, Wolfe GI, Benatar M, Evoli A, Gilhus NE, Illa I, Kuntz N, Massey JM, Melms A, Murai H, Nicolle M, Palace J, Richman DP, Verschuuren J, Narayanaswami P.

Neurology. 2016 Jul 26;87(4):419-25. doi: 10.1212/WNL.0000000000002790. Epub 2016 Jun 29. Review.

9.

Myasthenia gravis exacerbation after discontinuing mycophenolate: A single-center cohort study.

Oskarsson B, Rocke DM, Dengel K, Richman DP.

Neurology. 2016 Mar 22;86(12):1159-63. doi: 10.1212/WNL.0000000000002405. Epub 2016 Feb 5.

10.

Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine.

Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, Benatar M, Bird SJ, Bromberg M, Chahin N, Ciafaloni E, Cohen JA, Corse A, Crum BA, David WS, Dimberg E, Sousa EA, Donofrio PD, Dyck PJ, Engel AG, Ensrud ER, Ferrante M, Freimer M, Gable KL, Gibson S, Gilchrist JM, Goldstein JM, Gooch CL, Goodman BP, Gorelov D, Gospe SM Jr, Goyal NA, Guidon AC, Guptill JT, Gutmann L, Gutmann L, Gwathmey K, Harati Y, Harper CM Jr, Hehir MK, Hobson-Webb LD, Howard JF Jr, Jackson CE, Johnson N, Jones SM, Juel VC, Kaminski HJ, Karam C, Kennelly KD, Khella S, Khoury J, Kincaid JC, Kissel JT, Kolb N, Lacomis D, Ladha S, Larriviere D, Lewis RA, Li Y, Litchy WJ, Logigian E, Lou JS, MacGowen DJ, Maselli R, Massey JM, Mauermann ML, Mathews KD, Meriggioli MN, Miller RG, Moon JS, Mozaffar T, Nations SP, Nowak RJ, Ostrow LW, Pascuzzi RM, Peltier A, Ruzhansky K, Richman DP, Ross MA, Rubin DI, Russell JA, Sachs GM, Salajegheh MK, Saperstein DS, Scelsa S, Selcen D, Shaibani A, Shieh PB, Silvestri NJ, Singleton JR, Smith BE, So YT, Solorzano G, Sorenson EJ, Srinivasen J, Tavee J, Tawil R, Thaisetthawatkul P, Thornton C, Trivedi J, Vernino S, Wang AK, Webb TA, Weiss MD, Windebank AJ, Wolfe GI.

Muscle Nerve. 2016 Feb;53(2):165-8. doi: 10.1002/mus.25009. Epub 2015 Dec 21. No abstract available.

PMID:
26662952
11.

The Future of Research in Myasthenia.

Richman DP.

JAMA Neurol. 2015 Jul;72(7):812-4. doi: 10.1001/jamaneurol.2014.4740. Review. No abstract available.

PMID:
26011044
12.

How clinical trials of myasthenia gravis can inform pre-clinical drug development.

Rostedt Punga A, Kaminski HJ, Richman DP, Benatar M.

Exp Neurol. 2015 Aug;270:78-81. doi: 10.1016/j.expneurol.2014.12.022. Epub 2015 Jan 13.

13.

Myasthenia gravis and related disorders: Pathology and molecular pathogenesis.

Ha JC, Richman DP.

Biochim Biophys Acta. 2015 Apr;1852(4):651-7. doi: 10.1016/j.bbadis.2014.11.022. Epub 2014 Dec 6. Review.

14.

Structural characterization of the main immunogenic region of the Torpedo acetylcholine receptor.

Morell SW, Trinh VB, Gudipati E, Friend A, Page NA, Agius MA, Richman DP, Fairclough RH.

Mol Immunol. 2014 Mar;58(1):116-31. doi: 10.1016/j.molimm.2013.11.005. Epub 2013 Dec 11. Erratum in: Mol Immunol. 2014 May;59(1):117.

PMID:
24333757
15.

Limited utility of current MRI criteria for distinguishing multiple sclerosis from common mimickers: primary and secondary CNS vasculitis, lupus and Sjogren's syndrome.

Kim SS, Richman DP, Johnson WO, Hald JK, Agius MA.

Mult Scler. 2014 Jan;20(1):57-63. doi: 10.1177/1352458513491329. Epub 2013 Jun 4.

PMID:
23736535
16.

Animal models of antimuscle-specific kinase myasthenia.

Richman DP, Nishi K, Ferns MJ, Schnier J, Pytel P, Maselli RA, Agius MA.

Ann N Y Acad Sci. 2012 Dec;1274:140-7. doi: 10.1111/j.1749-6632.2012.06782.x.

17.

Dominantly inherited myotonia congenita resulting from a mutation that increases open probability of the muscle chloride channel CLC-1.

Richman DP, Yu Y, Lee TT, Tseng PY, Yu WP, Maselli RA, Tang CY, Chen TY.

Neuromolecular Med. 2012 Dec;14(4):328-37. doi: 10.1007/s12017-012-8190-1. Epub 2012 Jul 12.

18.

Treatment of myasthenia gravis based on its immunopathogenesis.

Kim JY, Park KD, Richman DP.

J Clin Neurol. 2011 Dec;7(4):173-83. doi: 10.3988/jcn.2011.7.4.173. Epub 2011 Dec 29.

19.

Acute severe animal model of anti-muscle-specific kinase myasthenia: combined postsynaptic and presynaptic changes.

Richman DP, Nishi K, Morell SW, Chang JM, Ferns MJ, Wollmann RL, Maselli RA, Schnier J, Agius MA.

Arch Neurol. 2012 Apr;69(4):453-60. doi: 10.1001/archneurol.2011.2200. Epub 2011 Dec 12.

20.

Antibodies to low density lipoprotein receptor-related protein 4 in seronegative myasthenia gravis.

Richman DP.

Arch Neurol. 2012 Apr;69(4):434-5. doi: 10.1001/archneurol.2011.2855. Epub 2011 Dec 12. No abstract available.

21.

Accelerated central nervous system autoimmunity in BAFF-receptor-deficient mice.

Kim SS, Richman DP, Zamvil SS, Agius MA.

J Neurol Sci. 2011 Jul 15;306(1-2):9-15. doi: 10.1016/j.jns.2011.04.008. Epub 2011 May 6.

22.

Cerebral venous sinus thrombosis presenting with auditory hallucinations and illusions.

Wong VS, Adamczyk P, Dahlin B, Richman DP, Wheelock V.

Cogn Behav Neurol. 2011 Mar;24(1):40-2. doi: 10.1097/WNN.0b013e318217b0cd.

PMID:
21467920
23.

An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis.

Sanders DB, Hart IK, Mantegazza R, Shukla SS, Siddiqi ZA, De Baets MH, Melms A, Nicolle MW, Solomons N, Richman DP.

Neurology. 2008 Aug 5;71(6):400-6. doi: 10.1212/01.wnl.0000312374.95186.cc. Epub 2008 Apr 23.

PMID:
18434638
24.

Variable phenotypes associated with mutations in DOK7.

Anderson JA, Ng JJ, Bowe C, McDonald C, Richman DP, Wollmann RL, Maselli RA.

Muscle Nerve. 2008 Apr;37(4):448-56.

PMID:
18161030
25.

Treatment of autoimmune myasthenia gravis.

Richman DP, Agius MA.

Neurology. 2003 Dec 23;61(12):1652-61. Review.

PMID:
14694025
26.

Treatment principles in the management of autoimmune myasthenia gravis.

Richman DP, Agius MA.

Ann N Y Acad Sci. 2003 Sep;998:457-72.

PMID:
14592915
27.

Three forms of immune myasthenia.

Agius MA, Richman DP, Fairclough RH, Aarli J, Gilhus NE, Romi F.

Ann N Y Acad Sci. 2003 Sep;998:453-6.

PMID:
14592914
28.

Agonist-induced transitions of the acetylcholine receptor.

Fairclough RH, Agius MA, Gudipati E, Silvian L, Hamaoka B, Beltzner CC, Lin MY, Chuang AR, Richman DP.

Ann N Y Acad Sci. 2003 Sep;998:101-13.

PMID:
14592867
29.

Thymectomy in the treatment of ocular myasthenia gravis.

Roberts PF, Venuta F, Rendina E, De Giacomo T, Coloni GF, Follette DM, Richman DP, Benfield JR.

J Thorac Cardiovasc Surg. 2001 Sep;122(3):562-8.

30.

Presynaptic congenital myasthenic syndrome due to quantal release deficiency.

Maselli RA, Kong DZ, Bowe CM, McDonald CM, Ellis WG, Agius MA, Gomez CM, Richman DP, Wollmann RL.

Neurology. 2001 Jul 24;57(2):279-89.

PMID:
11468313
31.

Differential surface accessibility of alpha(187-199) in the Torpedo acetylcholine receptor alpha subunits.

Fairclough RH, Twaddle GM, Gudipati E, Lin MY, Richman DP.

J Mol Biol. 1998 Sep 18;282(2):317-30.

PMID:
9735290
32.

Mapping the mAb 383C epitope to alpha 2(187-199) of the Torpedo acetylcholine receptor on the three-dimensional model.

Fairclough RH, Twaddle GM, Gudipati E, Stone RJ, Richman DP, Burkwall DA, Josephs R.

J Mol Biol. 1998 Sep 18;282(2):301-15.

PMID:
9735289
33.

Expression and initial characterization of recombinant antiacetylcholine receptor antibodies in experimental autoimmune myasthenia gravis.

Kirvan CA, Zhu S, Richman DP, Agius MA.

Ann N Y Acad Sci. 1998 May 13;841:466-8. No abstract available.

PMID:
9668275
34.

Antibody effector mechanisms in myasthenia gravis. The complement hypothesis.

Richman DP, Agius MA, Kirvan CA, Gomez CM, Fairclough RH, Dupont BL, Maselli RA.

Ann N Y Acad Sci. 1998 May 13;841:450-65. Review. No abstract available.

PMID:
9668274
35.

MAb 383C binds to the alpha-subunit of the acetylcholine receptor associated with the high-affinity tubocurarine site.

Lin MY, Twaddle GM, Gudipati E, Richman DP, Fairclough RH.

Ann N Y Acad Sci. 1998 May 13;841:101-3. No abstract available.

PMID:
9668226
36.

A role for alpha(187-199) in the conversion of agonist binding energy to the opening of the acetylcholine receptor ion channel.

Fairclough RH, Gudipati E, Lin MY, Twaddle GM, Richman DP, Burkwall DA, Josephs R.

Ann N Y Acad Sci. 1998 May 13;841:87-92. No abstract available.

PMID:
9668223
37.

Cluster of wound botulism in California: clinical, electrophysiologic, and pathologic study.

Maselli RA, Ellis W, Mandler RN, Sheikh F, Senton G, Knox S, Salari-Namin H, Agius M, Wollmann RL, Richman DP.

Muscle Nerve. 1997 Oct;20(10):1284-95.

PMID:
9324085
38.

Neurology.

Richman DP.

West J Med. 1995 Nov;163(5):470. No abstract available.

39.

Pathogenesis of hyperacute experimental autoimmune myasthenia gravis. Acetylcholine receptor/cholinergic site/receptor function/autoimmunity.

Mihovilovic M, Donnelly-Roberts D, Richman DP, Martinez-Carrion M.

J Immunol. 1994 Jun 15;152(12):5997-6002.

PMID:
8207224
40.

Myasthenia gravis: pathogenesis and treatment.

Richman DP, Agius MA.

Semin Neurol. 1994 Jun;14(2):106-10. Review.

PMID:
7984824
41.

Acquired myasthenia gravis. Immunopathology.

Richman DP, Agius MA.

Neurol Clin. 1994 May;12(2):273-84. Review.

PMID:
8041342
42.

Transcervical thymectomy for myasthenia gravis.

DeFilippi VJ, Richman DP, Ferguson MK.

Ann Thorac Surg. 1994 Jan;57(1):194-7.

PMID:
8279889
43.

Neuromuscular transmission in amyotrophic lateral sclerosis.

Maselli RA, Wollman RL, Leung C, Distad B, Palombi S, Richman DP, Salazar-Grueso EF, Roos RP.

Muscle Nerve. 1993 Nov;16(11):1193-203.

PMID:
8105377
44.

Molecular structure of a monoclonal antiacetylcholine receptor antibody and of a corresponding monoclonal antiidiotopic antibody.

Agius MA, Sanyal B, Richman DP.

Ann N Y Acad Sci. 1993 Jun 21;681:274-5. No abstract available.

PMID:
8357167
45.

Effector mechanisms of myasthenic antibodies.

Richman DP, Wollmann RL, Maselli RA, Gomez CM, Corey AL, Agius MA, Fairclough RH.

Ann N Y Acad Sci. 1993 Jun 21;681:264-73. No abstract available.

PMID:
8357166
46.

An immunogenic self-peptide for T cells in mice with experimental myasthenia.

Xu Q, Agius M, Gudipati E, Fairclough RH, Richman DP.

Ann N Y Acad Sci. 1993 Jun 21;681:1-4. No abstract available.

PMID:
8357155
47.

Effects of D-penicillamine on multiple immunogenic epitopes of the acetylcholine receptor.

Xu Q, Fairclough RH, Richman DP.

Ann N Y Acad Sci. 1993 Jun 21;681:335-8. No abstract available.

PMID:
7689309
48.

Characterization of the epitope of an antiacetylcholine receptor antibody that inhibits fifty percent of alpha-bungarotoxin binding.

Xu Q, Twaddle GM, Richman DP, Fairclough RH.

Ann N Y Acad Sci. 1993 Jun 21;681:175-8. No abstract available.

PMID:
7689304
49.

Interaction of antiacetylcholine receptor monoclonal antibodies with the acetylcholine receptor.

Xu Q, Fairclough RH, Richman DP.

Ann N Y Acad Sci. 1993 Jun 21;681:172-4. No abstract available.

PMID:
7689303
50.

Imaging ligand binding sites on the Torpedo acetylcholine receptor.

Fairclough RH, Josephs R, Richman DP.

Ann N Y Acad Sci. 1993 Jun 21;681:113-25. No abstract available.

PMID:
7689302

Supplemental Content

Loading ...
Support Center